Neumora Therapeutics, Inc. Common StockNMRANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.69% | +1.36% | +2.22% | +1.70% | +1.42% |
| Weighted Average Shares Diluted Growth | +2.69% | +1.36% | +2.22% | +1.70% | +1.42% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | -100.00% | -100.00% | -100.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -35.28% | -36.12% | -42.97% | -44.66% | -49.56% |
| Book Value per Share Growth | -39.08% | -39.62% | -47.38% | -52.84% | -59.37% |
| Debt Growth | -55.31% | -64.58% | -78.82% | +453.40% | -80.95% |
| R&D Expense Growth | +45.74% | +18.14% | +13.97% | -20.37% | -33.17% |
| SG&A Expenses Growth | +4.93% | +53.66% | +31.21% | +0.80% | -23.95% |